<DOC>
	<DOCNO>NCT02279394</DOCNO>
	<brief_summary>This research study aim determine proportion high risk smolder multiple myeloma patient progression free 2 year receive elotuzumab , lenalidomide dexamethasone combination therapy .</brief_summary>
	<brief_title>Trial Combination Elotuzumab Lenalidomide Dexamethasone High-Risk Smoldering Multiple Myeloma</brief_title>
	<detailed_description>This research study Phase II clinical trial , test effectiveness investigational drug elotuzumab , lenalidomide dexamethasone smolder multiple myeloma . Recent research study show early treatment smolder multiple myeloma may delay prevent progression active multiple myeloma . The purpose research study learn whether combination elotuzumab , lenalidomide dexamethasone work treat smolder multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age ≥ 18 year Must smolder myeloma high risk marker base Mayo OR Spanish criterion describe &gt; 10 % plasma cell bone marrow one following : Serum M protein 3 g/dL great IgA SMM Immunoparesis reduction two uninvolved immunoglobulin isotypes Serum involved/uninvolved free light chain ratio ≥8 ( less 100 ) Progressive increase M protein level ( Evolving type SMM ) † Bone marrow clonal plasma cell 5060 % Abnormal plasma cell immunophenotype ( ≥95 % bone marrow plasma cell clonal ) reduction one uninvolved immunoglobulin isotypes ( 4 ; 14 ) del 17p 1q gain Increased circulate plasma cell MRI diffuse abnormalities 1 focal lesion PETCT focal lesion increase uptake without underlie osteolytic bone destruction † Increase serum monoclonal protein ≥25 % two successive evaluation within 6 month period No evidence CRAB ( see detail ) criteria new criterion active multiple myeloma include follow : Increased calcium level ( correct serum calcium &gt; 0.25 mmol/dL upper limit normal &gt; .275 mmol/dL ) Renal insufficiency ( attributable myeloma ) Anemia ( Hb 2g/dL low limit normal &lt; 10g/dL ) Bone lesion ( lytic lesion generalize osteoporosis compression fracture ) No evidence follow new criterion active MM include follow : Bone marrow plasma cell ≥ 60 % , Serum involved/uninvolved FLC ratio ≥100 , MRI one focal lesion Participants CRAB criterion attributable condition disease study may eligible ECOG Performance Status ( PS ) 0 , 1 , 2 ( Appendix A ) The following laboratory value obtain ≤ 14 day prior registration : ANC ≥1000/µL PLT ≥ 50,000/µL Total bilirubin ≤ 2.0 mg/dL ( If total elevate check direct normal patient eligible . ) AST ≤ 3 x institutional upper limit normal ( ULN ) ALT ≤ 3 x institutional upper limit normal ( ULN ) Estimated creatinine clearance ≥ 60mL/min creatinine ≤ 2.2 mg/dL Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Females childbearing potential* must negative serum urine pregnancy test Men must agree use latex condom sexual contact female childbearing potential even successful vasectomy Ability understand willingness sign write informed consent . Symptomatic Multiple Myeloma evidence CRAB criterion include new criterion overt myeloma . Any prior therapy active Myeloma also exclude . Prior therapy smolder myeloma exclusion criterion . Bisphosphonates exclude Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational . Prior therapy bisphosphonate allow . Prior radiation therapy solitary plasmacytoma allow . Prior clinical trial smolder MM MGUS allow long last therapy least 2 month prior improvement M spike Serious medical psychiatric illness likely interfere participation clinical study Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Uncontrolled intercurrent illness History allergic reaction attribute compound similar chemical biologic composition elotuzumab lenalidomide Known seropositive active viral infection human immunodeficiency virus , hepatitis B virus hepatitis C virus . Patients seropositive hepatitis B virus vaccine eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Smoldering myeloma</keyword>
	<keyword>Smoldering Multiple Myeloma</keyword>
</DOC>